Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610717-26-000344
Filing Date
2026-07-30
Accepted
2026-07-30 17:05:41
Documents
2
Period of Report
2026-07-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 form3.html 3  
1 FORM 3 form3.xml 3 1719
2 POWER OF ATTORNEY charlesfuchs_poa.htm EX-24.1 7856
  Complete submission text file 0001610717-26-000344.txt   11085
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
Fuchs Charles S. (Reporting) CIK: 0001719576 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37587 | Film No.: 261224362